Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 7Phase 3 2Phase 4 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Neoplasms 2Urinary Bladder Neoplasms 1Strabismus 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1Pain 1Ovarian Neoplasms 1Obesity 1Multiple Myeloma 1Mucositis 1Lung Neoplasms 1Insulin Resistance 1Infertility, Female 1Infertility 1Hyperphagia 1Hyperglycemia 1Febrile Neutropenia 1Emergence Delirium 1

Interventions

Dexamethasone 11Lenalidomide 10Bortezomib 9Zoledronic Acid 8ixazomib 4daratumumab 4Melphalan 4tocilizumab 3Thalidomide 3Cyclophosphamide 3pomalidomide 2carfilzomib 2Prednisone 2Kyphoplasty 2Filgrastim 2Doxorubicin 2Calcium Dobesilate 2zanubrutinib 1talquetamab 1pegylated granulocyte colony-stimulating factor 1montelukast 1isatuximab 1ibrutinib 1exifone 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1apixaban 1Vaccination 1Thiotepa 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Multiple Myeloma × Injections × Clear all
NCT06425276 2024-05-23

Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantation

CASI Pharmaceuticals (China) Co., Ltd.

Phase 4 Completed
67 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡